Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Kamada plans to initiate the development of an Anti-Corona polyclonal immunoglobulin using its proprietary plasma derived IgG platform technology for severely ill coronavirus patients.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
November 03, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable